- Home
- AUPH
as 08-18-2025 4:00pm EST
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Founded: | 1993 | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 1.4B | IPO Year: | 1999 |
| Target Price: | $12.25 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.23 - $12.53 | Next Earning Date: | 07-31-2025 |
| Revenue: | $260,111,000 | Revenue Growth: | 25.59% |
| Revenue Growth (this year): | 12.15% | Revenue Growth (next year): | 18.34% |
Latest Aurinia Pharmaceuticals Inc News
AUPH Breaking Stock News: Dive into AUPH Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns
Zacks
3 months ago
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Business Wire
3 months ago
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Simply Wall St.
3 months ago
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest
Simply Wall St.
3 months ago
Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next
Zacks
3 months ago
Company News for May 13, 2025
GuruFocus.com
3 months ago
Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Zacks
3 months ago
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
Compare AUPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.